Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Nascobal Nasal Spray submitted for FDA approval

Jan. 7, 2004

Shipments of TriNessa commence

Jan. 7, 2004

Coremed plans clinical trials for Alveair insulin technology

Jan. 7, 2004

Aventis scientists prepare and test new cathepsin K inhibitors

Jan. 7, 2004

Insight into the mechanism of the antilipemic effects of FR-218944

Jan. 5, 2004

Bislactone-based acetyl-CoA carboxylase inhibitors newly identified at Ajinomoto

Jan. 5, 2004

Nastech submits abbreviated NDA for Calcitonin-Salmon nasal spray

Jan. 5, 2004

Cardiome submits oxypurinol NDA

Jan. 5, 2004

Extended phase I trial of INT for diabetes

Jan. 5, 2004

Otsuka describes novel thiourea derivatives for diabetes and obesity

Dec. 30, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...